Ernexa Therapeutics Inc. Interest Expense Nonoperating
Ernexa Therapeutics Inc. (ERNA) reported Interest Expense Nonoperating of -$100.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-03-13
- Ernexa Therapeutics Inc. interest expense nonoperating for the quarter ending 2025-03-31 was $800.00K, a 700.00% increase year-over-year.
- Ernexa Therapeutics Inc. interest expense nonoperating for the quarter ending 2024-12-31 was -$10.10M.
- Ernexa Therapeutics Inc. interest expense nonoperating for the quarter ending 2024-09-30 was $1.70M.
- Ernexa Therapeutics Inc. interest expense nonoperating for the quarter ending 2024-06-30 was $800.00K.
- Ernexa Therapeutics Inc. interest expense nonoperating for fiscal 2025 was -$100.00K.
- Ernexa Therapeutics Inc. interest expense nonoperating for fiscal 2024 was -$6.80M, a 1460.00% decline from fiscal 2023.
- Ernexa Therapeutics Inc. interest expense nonoperating for fiscal 2023 was $500.00K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month | Interest Expense Nonoperating 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -$100.00K 10-K · filed 2026-03-13 | ||||
| 2025-03-31 | $800.00K 10-Q · filed 2025-05-07 | -$9.30M derived: sum of 2 quarters · filed 2026-03-13 | -$7.60M derived: sum of 3 quarters · filed 2026-03-13 | -$6.80M derived: sum of 4 quarters · filed 2026-03-13 | |
| 2024-12-31 | -$10.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$8.40M derived: sum of 2 quarters · filed 2026-03-13 | -$7.60M derived: sum of 3 quarters · filed 2026-03-13 | -$6.80M 10-K · filed 2026-03-13 | $6.50M 10-K · filed 2025-03-12 |
| 2024-09-30 | $1.70M 10-Q · filed 2025-11-07 | $2.50M derived: sum of 2 quarters · filed 2025-11-07 | $3.30M 10-Q · filed 2025-11-07 | ||
| 2024-06-30 | $800.00K 10-Q · filed 2025-08-13 | $1.60M 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | $100.00K 10-Q · filed 2025-05-07 | ||||
| 2023-12-31 | $500.00K 10-K · filed 2025-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |